anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a humanized breast cancer antigen and an antibody thereof. The amino acid residue sequence of the antigen is shown in a sequence list 1. The antigen is a natural antigen or a recombinant protein antigen, which is mainly expressed in cancer cells of the human breast cancer, but is not expressed in human normal cells; and the antigen can be used as a target point of human breast cancer active immunotherapy or prevention and as a target point of various targeted immunological therapies. The invention also provides an antibody resistant to the humanized breast cancer antigen. The antibody is a polyclonal antibody, a mouse monoclonal antibody or antibody segment, and derivates of the antibodies, wherein the derivates comprise the antibody crosslinked with nuclide, the antibody crosslinked with chemical medicaments, the antibody crosslinked with liposome, the antibody fused with a medicament preemzyme, the antibody fused with other effector molecules and the like. The invention also provides application of the antibody and derivates resistant to the humanized breast cancer antigen Hv1 in the preparation of medicaments for diagnosing, treating and preventing human breast cancer.
Arm 2 will receive TME. Surgery including high ligation of the inferior mesenteric artery and total mesorectal excision will be performed under the lithotomy position. After pelvic dissection, double-stapled anastomosis or transanal anastomosis will be performed, followed by diverting stoma. Abdominoperineal resection with permanent stoma is included.
The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
Subjects will be given one Avelox® 400mg (Moxifloxacin HCl) Tablet (1x400mg), manufactured by Bayer HealthCare, after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time-point. Blood samples will be taken up to 72.0 hours post-dose.
Healthy volunteers who met the inclusion criteria were included in the study upon agreement to participate. The participants were divided into two groups. One group received 6 weeks of general upper extremity exercises along with proprioceptive exercise training. The proprioceptive exercise training consisted of a 10-minute warm-up period including active and passive upper extremity exercises followed by 30 minutes of proprioceptive exercises. The exercise program progressed weekly, and exercises were performed in standardized positions. To ensure adherence to the exercises, they were recorded on video and sent to participants' phones. The second group performed general upper extremity exercises for 6 weeks. The reason for creating the second group was to eliminate the time-dependent effect of changes in electromyographic activation levels of muscles. Additionally, the bilateral effects of unilateral upper extremity exercise training are observed. Comparing the electromyographic activities of untrained healthy individuals at the end of the treatment may enhance the quality of data interpretation. However, other factors that increase the risk of error in evaluating distal motor performance of the upper extremity were also considered in our study. It is expected that the motor performance of the dominant side will be greater than that of the non-dominant side. However, the non-dominant side is more frequently used in daily activities, resulting in a higher frequency and intensity of daily life activities being loaded onto the dominant side. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the healthy individuals participating in our study. Detailed evaluations were performed on the individuals participating in the study, as described below. Evaluations were conducted twice, before starting the exercise program and after the 6-week exercise program.
Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
Diabetes mellitus (DM) is an important health problem all over the world, which mostly starts in middle and advanced ages and has an important place among non-communicable chronic diseases due to its high morbidity and mortality. It can affect the patient biologically, psychologically, socially and psychosexually. In addition, generalized anxiety disorder was observed in 14% of the patients and an increase in anxiety levels was observed in 40%. Meta-analyses have shown that the presence of diabetes in an individual has a 24% risk of developing depression. This increase in depression and anxiety in DM negatively affects the patient's compliance and response to treatment and the prognosis of the disease. In addition, it causes deterioration in self-care and quality of life, the risk of developing complications, morbidity, mortality and health expenditures. Progressive relaxation exercise (PGE) is the voluntary contraction and relaxation of large muscle groups in the body, and noticing the difference. The PGE technique, developed by Jacobson in 1934, is based on the idea that anxiety-provoking thoughts and events create physiological tension. Doctor Edmund Jacobson developed the PGE to raise awareness of skeletal muscle tension. Muscle tension is triggered by various negative emotions and psychosomatic diseases. With this exercise, relaxation is aimed to reduce the feeling of tension and the perceived stress level. Progressive relaxation exercises are an inexpensive method that can be easily taught by nurses, yoga instructors, clinical psychologists, and other complementary alternative medicine practitioners. PGE is performed one-on-one or as a group, in one or several sessions, with the help of a CD or sound recorder. In order to increase its effectiveness, it can be applied with musical accompaniment, visual imagery or diaphragmatic breathing. Deep relaxation can be used to prevent the tensions experienced after stressful events from harming the body; It is one of the physiological and psychological relaxation methods such as sports and sleep. It is very useful for maintaining physical and mental health. It is suggested that a deep relaxation exercise that usually lasts 25-30 minutes can provide a benefit close to the benefit of two hours of deep sleep. In the literature, it is stated that if these exercises can be performed consistently and systematically for a long time, they have positive effects on stress-based insomnia, migraine pain, diabetes and high blood pressure. When we look at the literature, it has been determined that progressive relaxation exercises have a positive effect on anxiety and quality of life in many disease groups, but it has been observed that there are not enough studies in which these exercises are applied in diabetes patients and their effects on anxiety and quality of life are examined. The research is important in that it will examine the effect of progressive relaxation exercises on anxiety and quality of life, which is essential for diabetic patients.
Children who are deaf/hard of hearing will receive standard of care speech and language therapy with a speech language pathologist. Reading time is prescribed 20 min, 3x/week.
Patients with positive blood cultures from 2018 and 2019 receiving a new identification method (cases). The new identification method is the Biofire FilmArray© Blood Culture Identification (BCID) panel, a polymerase chain reaction-based method, performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies. The assays allow to identify a panel of 20 most commonly Gram-positive and -negative bacteria and yeast causing blood stream infections. It also allows to determine three resistance genes (mecA, vanA/B and KPC).
Metabolic targets are controversial in older people with type 2 diabetes due to functional heterogeneity and morbidity burden. Tight blood pressure and metabolic control appears beneficial in fit individuals who are newly diagnosed with type 2 diabetes and have fewer comorbidities. The benefits of low blood pressure and tight metabolic control is attenuated with the development of comorbidities, especially frailty. Guidelines consider frail older people as one category and recommend relaxed targets. However, sarcopenic obese frail individuals may benefit from tight targets and intensification of therapy due to their unfavourable metabolic profile, accelerated diabetes trajectory and high cardiovascular risk. In addition, the early use of sodium glucose transporter-2 inhibitors and glucagon like peptide-1 receptor agonists may be beneficial in this frailty phenotype due to their cardio-renal protection, which is independent of glycaemic control, provided they are able to engage in resistance exercise training to avoid loss of muscle mass. In the anorexic malnourished frail individual, early use of insulin, due to its weight gain and anabolic properties, is appropriate. In this phenotype, targets should be relaxed with deintensification of therapy due to significant weight loss, decelerated diabetes trajectory and increased risk of medication side effects.
This open-label, randomized study will assess the comparative effectiveness of two versus three active MDMA-assisted therapy sessions in U.S. military veterans with at least moderate chronic PTSD treated in an outpatient VA treatment clinic. The study will be conducted in up to 60 participants. Prior to the randomized portion of the study, each therapist pair team will treat one participant under the 3-session model, and one participant under the 2-session model. In total, 8 participants will be treated under this proof of principle therapist training lead-in. A 120 mg dose of MDMA, followed by a supplemental dose (60 mg) unless contraindicated, is administered during the treatment period with manualized psychotherapy in 2 or 3 open-label monthly Experimental Sessions. This \~ 8-12-week Treatment Period includes three Preparatory Sessions prior to the first MDMA-assisted session. During the treatment period, each Experimental Session is followed by three Integrative Sessions of non-drug therapy. The Primary Outcome measure, the change in CAPS-5 from Baseline, is assessed by a centralized, blinded Independent Rater (IR) pool at post-treatment for each group.
Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administration of peptide MBP75-95, either as a single dose, or as repeated injections for periods up to 10 weeks, produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A  control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP75-95 resulted in significant decline of F and B CSF anti-MBP levels over a period of one month. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP  epitope for MS anti-MBP has been localized to an area between Pro85 and Pro96.
PROBLEM TO BE SOLVED: To obtain the subject medicinal agent non-neurotoxic to hosts, capable of ceasing the protein synthesis in neuro cells through infection on the neuroma cell, also sensitive to acyclovir, by using a specific vector afforded by herpes simplex virus. SOLUTION: This apoptosis agent contains a vector obtained by removing γ1 34.5 gene from the gene of herpes simplex virus. The vector is e.g. R3616 as the recombinant virus of herpes simplex virus (HSV-1-d-34.5) which is pref. obtained by removing the 1kb base pairs in the DNA sequence containing the 34.5 gene in HSV-1 (specifically, it is recommended that the point corresponding to the 28th amino acid site in the γ1 34.5 gene is cut by the use of restriction enzyme BstE II along with cutting the 3'-terminal of the gene by the use of restriction enzyme Stu I. The dose of the vector is pref. 10 or more per oncocyte. This agent can be manufactured into a preparation by formulating the above vector with a stabilizer such an human serum albumin.
The study will establish factors fundamental to the improvement in communication and quality of life for people with dementia known as primary progressive aphasia (PPA). PPA is a type of dementia in which language declines but other cognitive skills (including memory) are preserved in the first several years after the onset (see Mesulam 1982). This makes those in the initial stages of PPA excellent candidates for treatment and creates a window of time (2-7 years) whereby PPA individuals can lead independent lives with minimal support. However, currently, no communication therapy is available to people with PPA due to the progressive nature of the disorder and lack of awareness of available options for professionals willing to treat it.

Naming impairments are omnipresent in PPA. For this reason, anomia will be the focus of our intervention. Participants with PPA in our study will receive two kinds of therapy for the words they cannot recall spontaneously, and will be trained to maintain them through social interaction. The type of training will be based on the most successful interventions the investigators provided to people with PPA in our previous work (active encoding and errorless lerning). The investigators expect that successful re-learning of forgotten words and practicing them in a group setting will facilitate retention of communication skills leading to greater personal independence and increased/maintained quality of life for people with PPA. half of the cohort (randomly determined) will then participate in a communication group where conversations are encouraged and half will attend "non-verbal" group meetings when they will paint, watch movies and engage in other activities not requiring talking. To evaluate the benefits of practicing the re-learned words in a social setting naming skills will be tested for each participant before and after individual and group interventions.
FIELD: biotechnology, genetic engineering. SUBSTANCE: invention relates to bioengineering product used for control of fire ants and to method for preparing this product. Method involves the use of procedures of immunological and genetic engineering for the development of monoclonal antibodies mAb and viruses (phages) that elicit scFv fragments of heavy and/or light chain of Ig and exhibiting high degree of avidity in specific binding with middle intestine microfilament cells of mother of imported fire ants. Specific monoclonal antibodies and phages eliciting Fab fragments of antibodies bind with toxins for target delivery and damage of imported fire ant mothers and kill them but they do not affect the natural species. The usage of invention allows to recover the natural ecosystem due to selective effect of polypeptide prepared. EFFECT: improved preparing method, enhanced effectiveness of control. 6 cl, 1 dwg, 7 ex
<P>PROBLEM TO BE SOLVED: To obtain an anticoagulant capable of preventing thrombogenesis by inhibiting the agglutination of platelet and enabling daily management by individual.  <P>SOLUTION: This anticoagulant contains deep seawater or its desalted product as an active component. The anticoagulant has platelet agglutination inhibiting action and is effective for the prevention of thrombosis. It is safely administrable daily by individual. The anticoagulant can be administered as a drug or in various forms e.g. foods or drinks such as health food (preferably a functional food) or feed. Drink is included in the category of the food.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Keloids are fibroproliferative diseases featuring abnormal fibroblast proliferation and extracellular matrix (ECM) deposition. Current therapeutic methods for keloids are unsatisfactory, and the recurrence rates of keloids are high. Astragaloside IV (AS-IV) is a key active component of Astragalus membranaceus Bunge, and has been reported to exert potent anti-fibrotic effects. Accordingly, our research aimed to explore whether AS-IV suppresses fibroblast dysfunction and skin fibrosis during the development of keloids. Human keloid-derived fibroblasts (KFs) were stimulated by TGF-β1 to evaluate the influence of AS-IV on abnormal proliferation, migration, and accumulation of ECM in vitro. A bleomycin (BLM)-induced skin fibrosis model was established to assess the influence of AS-IV on ECM deposition and skin fibrosis in vivo. TGF-β1 stimulation enhanced the proliferation, migration, and accumulation of ECM in KFs, which were abolished by AS-IV treatment. The in vivo assay revealed that AS-IV administration restrained ECM accumulation and skin fibrosis in mouse models. AS-IV plays an anti-fibrotic role in keloids by suppressing fibroblast dysfunction and reducing ECM deposition.
TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.
Most persons with dementia exhibit behavioral symptoms, such as agitation and passivity, at some time in the course of their illness. These behaviors are a source of caregiver burden and often precipitate nursing home placement. There are a number of drugs that can be used to treat these behaviors, but they are costly and have serious adverse effects in a sizable number of people. Non-drug interventions, such as recreational activities, are recommended as the first line of treatment for behavioral symptoms. However, we don't know which activities are most effective for individual residents. The "one size fits all" approach has not been very effective. We are testing an approach that individualizes activities for residents based on their personality style of interest and functional level. We anticipate that this approach will be more effective for reducing behavioral symptoms than routine activities given to all residents. Consenting residents are assessed for personality and functional level and are videotaped during a baseline period and during activities so we can reliably measure behaviors, affect and engagement.
IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.
The investigators conduct a randomized controlled trial among 70 healthy college students in Shanghai, China. These students fulfilling the recruitment criteria will be randomly divided into two parallel groups to receive either fish oil \[marine-derived n-3 polyunsaturated fatty acids (PUFA)\] or sunflower seed oil. Participants in fish oil group receive 2.5 g/day (two 1.25-g capsules daily) in divided doses. The sunflower seed oil capsules are identical. All interventions started at 7:30 a.m.to avoid issues related to diurnal variation. Health endpoints, including blood pressure, skin color, fractional exhaled nitric oxide and pulmonary function were evaluated and biological samples such as morning urine, fast blood, saliva sample,buccal cells and skin tape stripping will be collected at week 1 before supplemenatation, and week 8, week 10, week 12 as well as week 14 during the supplementation phase.The investigators measure personal real-time exposure to PM2.5 and personal temperature and relative humidity.
Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.
Acute appendicitis, a common medical emergency, primarily affects children, and its diagnosis can be challenging. In addition to methods such as abdominal ultrasound, predictive clinical scales are used, such as the Alvarado scale and others, which categorize risk in pediatric patients. Given the lack of consensus on exact criteria, this review seeks to identify and analyze 22 prediction scales used in the diagnosis of acute appendicitis in children. The search was carried out according to the PRISMA guide, resulting in 73 articles selected from a total of 1521, with inclusion criteria focused on the pediatric population and integrated scales. The importance of predictive scales for appendicitis in children is highlighted, which incorporate clinical history, physical examination, laboratory and images to guide surgical intervention decisions. Among the most used worldwide were the Alvarado and Tzanakis scales, PAS and Heidelberg Appendicitis Score (HAS), designed specifically for pediatric patients.
Oral dose of sirolimus is calculated according to body surface area. Take it twice a day for 6 months. Maintain the blood concentration of sirolimus at 5-15ng/ml.
The diethylaminoethylisothiouronium chloride hydrochloride (DEAEITCHC) is used in the pharmaceutical industry, in particular for the preparation of antibiotics for the veterinary medicine. The method is realized when a mixture of equivalent quantities of 2-diethylaminoethylchloride hydrochloride and thiocarbamide are heated in a medium of aliphatic alcohol for 4 h at 65-84 deg. C. The reaction mass produced is cooled, the crystals are separated by filtration and are dried. The filtrate is subjected to a second concentration by evaporation in order to produce secondary crystals. The total yield of 2-diethylaminoethylisothiouronium chloride hydrochloride is over 93 %, the melting temperature is 190-194 deg. C, and the purity of the product exceeds 95 %. 1 claim